Summary.-The growth of a 3-methylcholanthrene-induced fibrosarcoma of C3H mice was inhibited by aspirin and indomethacin. While the tumour contained relatively high concentrations of PGE2-like material, that were markedly diminished by indomethacin treatment, our results did not confirm the recently proposed hypothesis that the anti-tumour effect arises from a restoration of depressed immune function. For example, mice that had completely eliminated their tumours under indomethacin administration were not immune to rechallenge. The tumour-bearing animals were not non-specifically immunodepressed, as their splenic PFC responses against SRBC were enhanced. However, while indomethacin augmented the PFC response in normal mice, this adjuvant effect was depressed in tumour-bearing animals. The spleen-cell PHA responses of tumour bearers were severely depressed, and such cells suppressed the PHA response of normal cells. Only after prolonged indomethacin treatment did animals (with comparable tumour burdens) show weak PHA responses and somewhat diminished suppressive activity.
Summary.-The growth of a 3-methylcholanthrene-induced fibrosarcoma of C3H mice was inhibited by aspirin and indomethacin. While the tumour contained relatively high concentrations of PGE2-like material, that were markedly diminished by indomethacin treatment, our results did not confirm the recently proposed hypothesis that the anti-tumour effect arises from a restoration of depressed immune function. For example, mice that had completely eliminated their tumours under indomethacin administration were not immune to rechallenge. The tumour-bearing animals were not non-specifically immunodepressed, as their splenic PFC responses against SRBC were enhanced. However, while indomethacin augmented the PFC response in normal mice, this adjuvant effect was depressed in tumour-bearing animals. The spleen-cell PHA responses of tumour bearers were severely depressed, and such cells suppressed the PHA response of normal cells. Only after prolonged indomethacin treatment did animals (with comparable tumour burdens) show weak PHA responses and somewhat diminished suppressive activity.
Possible alternative mechanisms, such as direct cytotoxicity, or inhibition of inflammation, phosphodiesterase activity, blood coagulation or calcium availability were not implicated (nor definitively excluded) in the anti-tumour effect.
TUMOUR growth in a number of experimental models is inhibited by non-steroid anti-inflammatory drugs such as aspirin and indomethacin (Strausser & Humes, 1975; Plescia et al., 1975; Hial et al., 1976 ). An immunological mechanism for this activity has been suggested on the basis of a series of observations, including the inhibition of prostaglandin synthesis by these drugs (Lewis, 1977 ) the high prostaglandin concentrations in many tumours (Strausser & Humes, 1975; Bennett et al., 1977; Sykes & Maddox, 1972 ) the immunological unresponsiveness of some tumour-bearing animals and immune "restoration" by indomethacin treatment (Plescia et al., 1975; Strausser & Humes, 1975; Pelus & Strausser, 1976) possibly via effects on "suppressor" cells (Goodwin et al., 1977; Webb & Jamieson, 1976) .
We have examined a 3-methylcholanthrene-induced transplantable fibrosarcoma of C3H mice (McC3-1) whose growth is also inhibited by indomethacin (Lynch & Salomon, in press J. Natl Cancer Inst. ) .
MATERIALS AND METHODS
Anirnals.-Male and female C3H/uip mice, 6 to 8 weeks old, were obtained from the breeding facilities of the IRSC, where they originally derived from C3H/HeJ stocks.
Tumoiirs.-Fibrosarcomas induced in C3H mice by the i.m. injection of 1 mg 3-methylcholanthrene were maintained by serial isogeneic transplantation and freezing of various passages. The McC3-I fibrosarcoma was used betweeii its 10th and 14th passages. Drug treaitment.-Indomethacin (Sigma) stored at -15°C as 10 mg/ml stocks in absolute ethanol was diluted 1/500 for administration in the drinking water (20 pug/ ml) which was changed 2 or 3 times per week. Mice drank between 4 and 6 ml per day (80 to 120 jug) and tolerated this dose for periods of at least 3 months without evident ill effects. In most experiments administration of the drug was begun when the tumour became palpable (about Day 7). I.p. administration was performed by the injection of 0-1 or 0-2 ml of a 1/20 dilution of the stock in phosphate-buffered saline (PBS). The alcohol vehicle was used as the control for both routes, and found to have no significant effect on tumour growth (tumour diameters of 16 3 ± 3-0 mm, compared to 16-6 ± 2-8 mm at Day 34 for oral administration and 19-6 + 3-9 mm for i.p. alcohol-PBS vs 20-1 i 3-5 mm for i.p. PBS).
Aspirin (lysinate, EGIC Amilly, France) theophylline (Bruneau, Paris) hydrocortisone (hemisuccinate, Roussel, Paris) and heparin (sodium, 120 u/mg, Choay, Paris), were used at the doses indicated in the Results section.
In vitro techniques.-Spleen-cell suspensions from groups of 5 mice were prepared in RPMI 1640 (Eurobio, Paris) supplemented with 2mM glutamine (Gibco, Grand Island, U.S.A.) and containing 500 fresh human AB or 10% foetal calf serum (decomplemented by heating at 56°C for 30 min), 100 u/ml penicillin and 100 ,ug/ml streptomycin. From 2-5 to 7.5 x 105 cells were placed in wells of Prostaglandin assay.-Freshly collected tissues were weighed, homogenized (UltraTurrax, 2 min, ice bath) in PBS, centrifuged (8000 g, 15 min) and then assayed by one of us (M.A.) on superfused rat fundic strips.
Three strips in series, under 2 g tension, were attached to an isotonic myograph and superfused (Na 138, K 2, Ca 3 5, Mg 1P5, Cl 107, CH3COO 38 and glucose 5-5 mEq/l, pH 7-2) at 5 ml/min, 37°C. Inhibitors of as and : adrenergic, cholinergic, histamine and serotonin activities were included in the superfusion fluid and control assays were performed on preparations with different pharmacologic sensitivities (rat colon and guinea-pig ileum) in order to verify the absence of PGF2ax, bradykinin, angiotensin II, and P substance. Dose-response curves to PGE2 were performed and the test samples assayed, at intervals of 15-20 min. The assay thus quantitated the PGE2-like" activity, and has been found to have a 1-01 ± 0 04 correlation with radioimmunoassay of solvent-extracted preparations (M.A. unpublished) and the presence of 15()4 PGE2 verified by silica-gel thin-layer chromatography using chloroform: methanol: acetic acid (18: 1: 1) as the developing solvent.
Statistics.-For normally distributed populations, mean i s.d. are presented and compared by Student's t test. In other cases the mean and range are presented and the nonparametric Mann-Whitney U test used. The exact factorial x2 test was used to compare proportions of small populations.
RESULTS

Effects of various drugs on tumour growth
The effect of aspirin and indomethacin on McC3-I tumour growth in C3H mice was compared with other drugs with activities like those expected from these 2 agents: anti-inflammation (hydrocortisone) inhibition of phosphodiesterase (theophylline) or anti-coagulation (heparin). In Table I [3H]TdR during 6 h on the 4th day of culture was measured. In all experiments, low indomethacin concentrations had no significant effect on cell proliferation, and higher concentrations were weakly stimulatory (e.g., a control incorporation of 464 ± 86 ct/min for second passage cells vs. 1169 = 285 ct/min in 20 ,ug/ml indomethacin; a 2-5-fold stimulation, P < 0-001).
Prostaglandins and bone resorption in Table II . The concentration was considerably greater in the spleen and 29-day-old tumours than in other organs, the tumours having the highest levels in most assays. Indomethacin treatment (100 ,tg i.p., 3 times weekly) markedly reduced the concentrations in these tissues (Table II) .
As tumour-associated prostaglandins have been implicated in the bone-resorbing activity of certain tumours, we also examined the effect of i.m. transplanted McC3-1 on the morphology of the tibia, and plasma calcium levels, in the presence or absence of indomethacin. The tumour caused substantial bone destruction, and this was diminished by oral indomethacin (Fig. 2) . Plasma calcium levels were significantly (P < 0 001) higher than normal (84 0 5 6K1 mg/l vs 63-2 ± 2 4 mg/l) but were reduced by indomethacin treatment (68.8 + 9-7 mg/l). S.c. grafted tumours minimally (though statistically significantly) raised plasma calcium levels above controls (91.2 ± 1-2 vs 88 0 ± 0-8 mg/l; P < 0.02).
Immunity after tumour regression
In order to test for persistent specific immunity against McC3-I in animals that had completely eliminated their tumours under indomethacin treatment, rechallenge grafts were performed. The second graft was given about 2 months after the first had completely regressed, to minimize non-specific influences that have occasionally been observed at earlier times, and when protective immunity (if present) is still detectable (unpublished (Lynch & Salomon, in press J. Natl Cancer Inst.). When such animals were regrafted 50 days after complete elimination of their tumours by C. parvum treatment alone, the second graft grew in 0/7 cases, and in 1/10 cases after C. parvum plus indomethacin. No inhibition of the growth of an unrelated 3-methylcholanthrene-induiced C3H fibrosarcoma (McC3-II) was observed in such animals.
Effect of tumour-and indomethacin on antibody synthesis
In a number of experiments the effect of idomethacin on the spleen direct PFC response to SRBC was examined in normal C3H, and those bearing McC3-I tumours of various sizes. It was found that continuous oral indomethacin administration (20 jug/ ml) commenced before immunization, but not simultaneously with the antigen, strongly enhanced the total and relative (/106 cells) spleen PFC response in normal animals ( Table III) . The number of PFC/106 spleen cells was not less than normal, in untreated tumour-bearing mice, even when the tumours were very large (e.g. 3-2 ± 1.9 g at Day 30; Table III ). In (2 x 105). The slower growth of the lower cell inoculum then matched that of the drug-treated tumours. Under these circumstances, long-term in vivo drug administration increased the PHA response of tumour bearers 6-fold (Table IV, Exp. 2a). However, even this enhanced response was still only 2500 of that of control animals. The addition of indomethacin in vitro at a low concentration slightly enhanced the effect of longterm in vivo administration of the drug (Table IV, Exp. 2b). Spleen cells from animals carrying the McC3-I tumours almost totally suppressed the PHA response of normal spleen cells (Table IV, Exp. 2c) but when the tumour-bearers were treated with indomethacin their cells caused only a moderate suppression of the normal response.
When supernatants from 3rd in vitro passage McC3-1 cultures were added to normal spleen cells, the PHA response of these was significantly (P < 0-001) augmented (Table V) . This enhancing activity (Strausser & Humes, 1975; Plescia et al., 1975; Hial et al., 1976) have found that the growth of experimental tumours in vivo can be inhibited, and the survival of the host prolonged, by the administration of aspirin or indomethacin. While these drugs may inhibit cell metabolism in some systems (Hial et al., 1976; , their activity against McC3-1 does not appear to be due to a direct cytotoxic or cytostatic effect, as low indomethacin concentrations had no significant effects on in vitro thymidine incorporation, and higher levels were slightly stimulatory. Comparable effects were observed by Santoro et al. (1976) .
It is unlikely (Strausser & Humes, 1975) that the reduced tumour sizes observed after the administration of these non-steroid anti-inflammatory drugs resulted simply from the removal of the inflammatory component, because survival times were significantly increased and complete elimination of McC3-I tumours occurred in some cases. Also hydrocortisone, a potent anti-inflammatory agent, did not significantly reduce the tumour size, although it did prolong the life of the tumour bearers. This effect on survival may have been due, however, to its influence on activities other than the inflammatory response per se (e.g., suppressor cells, Schechter & Feldman, 1977) . Also hydrocortisone, like aspirin and indomethacin, diminishes the production of prostaglandins (Tashjian et al., 1975) . These latter 2 drugs inhibit the cyclo-oxygenase catalysis of the preliminary step of the prostaglandin biosynthetic pathway (Lewis, 1977) . The McC3-I tumour, like many others (Strausser & Humes, 1975; Sykes & Maddox, 1972; Bennett et al., 1977) contains particularly high concentrations of prostaglandins, and these levels are markedly diminished by indomethacin treatment. It has been suggested that the immunosuppression described in some tumour-bearing animals results from the influence of these hormones on the immune system. Aspirin and indomethacin may, therefore, restore the immune function by inhibiting their synthesis (Plescia et al., 1975; Strausser & Humes, 1975; Pelus & Strausser, 1976) and thus augmenting the anti-tumour immune responses. This attractive hypothesis is not, however, necessarily supported by our results with the McC3-I tumour. Thus, while the in vivo growth of the tumour was markedly diminished by these drugs, we found no evidence of a generalized immunosuppression in untreated animals. The total primary anti-SRBC response was actually enhanced, even (or particularly) by large tumours.
No diminution of the serum IgG, and IgE titres against ovalbumin was observed in such animals (Lynch & Salomon, 1977a) . Like Webb & Osheroff (1976) we found that indomethacin pretreatment of normal mice enhanced the anti-SRBC response, but not when the drug was administered simultaneously with, or after, the antigen. Such an activity may, therefore, have little relevance to the McC3-I system, as the drug was administered only to animals carrying palpable tumours. It is possible, however, that the critical quantity of antigen required to trigger an immune response was only attained when the tumour reached a certain mass. We have in fact found that indomethacin exerted little effect on tumour growtlh until the tumours reached diameters of ' 10 mm (Lynch & Salomon, in press J. Natl Cancer Inst.). It should be noted that the McC3-I tumour appears to be weakly immunogenic in untreated animals, and even those that completely eliminated their tumours while receiving indomethacin showed no immunity. This contrasts with the situation where the tumours were rejected after i.t. C. parvum treatment, when lasting specific anti-tumour immunity was demonstrated. It is of interest that indomethacin treatment did not inhibit, but rather stimulated, the immunotherapeutic effect of C. parvum (Lynch & Salomon, in press J. Natl Cancer Inst.) and that such animals were equally immune.
As for the tumour systems described by Pelus & Strausser (1976) and Goodwin et al. (1977) the PHA response of lymphocytes from animals bearing McC3-I tumours was markedly lower than normal. This was not simply due to a dilution of the mitogen-sensitive cells in the greatly hyperplastic spleens, as such cells also suppressed the proliferative response of normal spleen cells. However, in contrast to those authors, we observed little restoration of the PHA response by shortterm in vivo or in vitro indomethacin administration. When the experimental design ensured comparable tumour burdens, long-term drug treatment was found to increase the P1IA response of tumour bearers 6-fold, to attain 25%0 of the normal level. As described in other systems (Goodwin et al., 1977; Webb and Jamieson, 1976) Thus, the hypothesis of a central role for the immune system in the anti-tumour activityT of aspirin and indomethacin can be questioned, at least for the McC3-I model. Indeed, these drugs possibly inhibit lymphocyte-mediated cytotoxicity (Winchurch et al., 1974) . We have yet to evaluate fully the contribution of possible alternative mechanisms. It appears, for example, unlikely that the effect of the drugs is due to inhibition (Coulson et al., 1977) of phosphodiesterase, as theophylline did not alter McC3-I growth. Theophylline has in fact been found to exert anti-tumour effects in some systems (Webb et al., 1972) but even these may result from prostaglandin antagonism (Manku & Horrobin, 1976) . Also, whilst aspirin and indomethacin can influence the bloodcoagulation system (e.g. by enhancing fibrinolysis; Moroz, 1977) and thus modify tumour growth (Hilgard & Thornes, 1976) heparin treatment was without effect on McC3-I. It is evident, however, that such possibilities can only be definitively excluded by more direct experimentation, and the use of drugs having similar overall effects via different mechanisms. That inhibition of prostaglandin synthesis is actually the basis of the indomethacin effect is suggested by preliminary (unpublished) experiments in which its anti-tumour activity was signi-.510 ficantly diminished by the daily i.p. injection of 1-5 Kg PGE2, although derivatives of this hormnone inhibit tumour growth in some systems (Santoro et al., 1976) .
It may also be postulated that by inhibiting the prostaglandin-associated bone-resorbing activity oftumours (Strausser & Humes, 1975; Powles et al., 1976; Atkins et al., 1977) indomethacin restricts the calcium available to the neoplastic cells (Strausser & Humes, 1975) . However, while i.m. grafted McC3-1 tumours caused indomethacin-inhibitable bone deformation identical to that previously described (Strausser & Humes, 1975) , only these, and not s.c. grafted tumours, produced clearly raised plasma calcium levels that were diminished by indomethacin treatment.
We are currently investigating the possibility that tumour-associated prostaglandins are responsible for the inhibition of anaphylactic-type reactions (Lewis, 1977; Dunn et al., 1976) in tumour bearing mice (Lynch & Salomon, 1977a) . Aspirin and indomethacin may, therefore, augment the activity of such reactions (Lewis, 1977) in tumour rejection (Lynch & Salomon, 1977b) .
